Covariates | Renal failure | Days of hospitalizations | Death | ||||||
OR | 95% CI | p value | OR | 95% CI | p value | OR | 95% CI | p value | |
Clinical pharmacologist consultation | 1.7 | 0.3 - 4.6 | 0.4 | 3.77 | 1.3 - 6.4 | 0.005 | 0.73 | 0.31 - 1.71 | 0.6 |
Acceptance of clinical pharmacologist recommendation | −0.78 | −14.59 - 13.03 | 0.9 | 4.88 | −2.14 - 11.88 | 0.2 | 3.94 | −4.94 - 12.82 | 0.4 |
Previous exposure to aminoglycosides | 14.2 | 2.39 - 85.51 | 0.004 | 0.26 | 1.3 - 2.33 | 0.8 | |||
Amikacin courses on high dose | 0.21 | 0.04 - 1.04 | 0.6 | 3.14 | −0.87 - 7.12 | 0.1 | 0.25 | 0.08 - 10.2 | 0.82 |
Amikacin courses more than 5 days | 0.36 | 0.08 - 1.51 | 0.08 | 0.07 | 0.4 - 2.45 | 0.87 | |||
Amikacin high serum TDM level | 1.01 | 0.71 - 12.17 | 0.12 | −0.02 | −1.23 - 0.08 | 0.7 | 0.26 | 0.19 - 8.95 | 0.78 |
Renal failure | −3.94 | −8.97 - 1.09 | 0.1 | 2.8 | 6.78 - 37.8 | <0.001 | |||
Amikacin Adverse Effects (AAEs) | 0.5 | 0.14 - 1.79 | 0.3 | 6.24 | −4.88 - 17.35 | 0.2 | |||
Hemodynamic instability and sepsis* | 31.3 | 2.89 - 336.99 | 0.005 | 8.59 | 3.49 - 18.5 | 0.001 | 2.5 | 2.05 - 38.65 | 0.001 |
Pneumonia | 3.94 | −4.94 - 12.82 | 0.38 | 9.2 | 6.06 - 12.25 | <0.001 | 3.6 | 1.59 - 8.11 | 0.002 |
Use of cardiovascular drugs | 4.8 | 1.33 - 17.52 | 0.01 | ||||||
Number hospitalizations without fluids administration | 0.22 | 0.48 - 176.62 | 0.14 |